http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( William Sievert ),( Huy Trinh ),( Giampiero Carosi ),( Ulus Akarca ),( Adrian Gadano ),( Francois Habersetzer ),( David Wong ),( Meghan Lovegren ),( Hui Zhang ),( Cyril Llamoso ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: The aim of this study was to elucidate the antiviral efficacy and safety of telbivudine in Korean treatment-naive chronic hepatitis B (CHB) patients. Methods: A total of 143 treatment-naive patients who had been treated with telbivudine for at least 6 months were consecutively enrolled. We determined the cumulative rates of virologic response (<12 IU/ml by PCR assay), serologic response, biochemical response and monitored any side effects. Results: The median age and follow-up duration were 50.7 years and 16.4 (range 6-24 months) months, respectively. Sixty seven patients (46.9%) were positive for HBeAg and the median serum HBV DNA level was 7.23 (range 4.31-8.26) log IU/ml. In HBeAg positive group, the cumulative probabilities of HBV DNA undetectability were 14.9% , 24.6%, 34.4% and 26.3% at 6, 12, 18 and 24 months, respectively. Partial virologic response at 6 months occurred in 82.1% of patients and inadequate virologic response at 6 months in 3.0%. During the follow-up period, 8 patients achieved HBeAg loss and 3 patients achieved HBeAg seroconversion. Meanwhile, in HBeAg-negative group, the cumulative rates of virologic response were 64.5%, 86.4%, 82.1% and 81.3%, respectively and the cumulative rates of biochemical response were 89.5%, 98.3%, 100% and 100%, respectively. Among the all patients, there were 42 cases of virologic breakthrough and 21 cases of genotypic resistance and virologic breakthrough. There were 46 (32.2%) cases of CK elevation and 2 (1.4%) cases of myopathy. However, there was no clinically significant safety issue. Conclusions: In Korean treatment-naive HBeAg-negative CHB patients, telbivudine therapy induced favorable virologic, serologic and biochemical responses.
( Robert G Gish ),( Ting Tsung Chang ),( Ching Lung Lai ),( Robert A De Man ),( Adrian Gadano ),( Song Yu ),( Cyril Llamoso ),( Hong Tang ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Entecavir (ETV) 0.5 mg demonstrated superior virologic, histologic, and biochemical benefit compared to lamivudine in phase III study ETV-022. Through 96 weeks of treatment and 24 weeks post-treatment follow-up, 5% of the patients achieved HBsAg loss. We present the changes in quantitative HBsAg levels in patients with HBeAg-positive nucleoside naive chronic hepatitis B patients treated with ETV in study ETV-022. Methods: The nucleoside-naive HBeAg-positive patients received ETV 0.5mg daily in study ETV-022. HBsAg levels were assessed qualitatively and quantitatively every 12 weeks. The quantitative HBsAg levels were measured with the Abbott Architect Assay. Mean HBsAg levels were calculated at baseline, week 12, 24, 36 and 48 for the overall cohort and cohorts with HBeAg loss or HBsAg loss. Results: A total of 95 ETV-treated patients from study ETV-022 had available blood samples and were analyzed for quantitative HBsAg levels. Baseline characteristics of patients include mean age 38 years old, mean HBV DNA 9.64 log10 copies/mL and ALT 156.65 U/L. The quantitative HBsAg levels over time in different patient groups are listed below Conclusion: Quantitative HBsAg levels decreased overtime during the first 48 weeks of ETV therapy in HBeAg-positive nucleoside naive patients. A greater declination in quantitative HBsAg value was observed among subjects who had HBeAg loss or HBsAg loss.
( Robert G Gish ),( Ting Tsung Chang ),( Ching Lung Lai ),( Robert A De Man ),( Adrian Gadano ),( Song Yu ),( Cyril Llamoso ),( Hong Tang ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Entecavir (ETV) 0.5 mg demonstrated superior virologic, histologic, and biochemical benefit compared to lamivudine in phase III study ETV-022. Through 96 weeks of treatment and 24 weeks post-treatment follow-up, 5% of the patients achieved HBsAg loss. We present the changes in quantitative HBsAg levels in patients with HBeAg-positive nucleoside naive chronic hepatitis B patients treated with ETV in study ETV-022. Methods: The nucleoside-naive HBeAg-positive patients received ETV 0.5mg daily in study ETV-022. HBsAg levels were assessed qualitatively and quantitatively every 12 weeks. The quantitative HBsAg levels were measured with the Abbott Architect Assay. Mean HBsAg levels were calculated at baseline, week 12, 24, 36 and 48 for the overall cohort and cohorts with HBeAg loss or HBsAg loss. Results: A total of 95 ETV-treated patients from study ETV-022 had available blood samples and were analyzed for quantitative HBsAg levels. Baseline characteristics of patients include mean age 38 years old, mean HBV DNA 9.64 log10 copies/mL and ALT 156.65 U/L. The quantitative HBsAg levels over time in different patient groups are listed below: Conclusion: Quantitative HBsAg levels decreased overtime during the first 48 weeks of ETV therapy in HBeAg-positive nucleoside naive patients. A greater declination in quantitative HBsAg value was observed among subjects who had HBeAg loss or HBsAg loss.
Lucas Jose Caram,Francisco Calderon,Esteban Masino,Victoria Ardiles,Ezequiel Mauro,Leila Haddad,Juan Pekolj,Jimena Vicens,Adrian Gadano,Eduardo de Santibanes,Martin de Santibanes 한국간담췌외과학회 2022 Annals of hepato-biliary-pancreatic surgery Vol.26 No.1
Backgrounds/Aims: The role of inflammation in malignant cell proliferation has been well described. High values of platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) as markers of systemic inflammation have shown associations with unfavorable long-term outcomes. The purpose of this study was to determine values of NLR and PLR evaluated prior to and after surgery and their associations with mortality and recurrence rates of liver transplant patients with hepatocellular carcinoma (HCC). Methods: A total of 105 patients with HCC who underwent orthotopic liver transplantation (OLT) were retrospectively reviewed. NLR and PLR values were obtained from complete blood counts prior to and after surgery. Overall survival (OS) and recurrence-free survival (RFS) in relation with delta NLR and PLR were estimated. Results: Serum alpha-fetoprotein levels > 100 ng/mL (p = 0.014) and lymphovascular emboli in the specimen (p = 0.048) were identified to be significant predictors of RFS. Child-Pugh score (p = 0.016) was found to be an independent factor associated with poorer OS. An increasing delta PLR was associated with worse RFS, although it showed no significant association with OS. Conclusions: The analysis of PLR as a continuous variable may predict recurrence outcomes in patients undergoing OLT for HCC. It is more representative than isolated values.